Immunology meets bioengineering: Improving the effectiveness of glioblastoma immunotherapy

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authoridAtefeh Zarepour / 0000-0002-0347-5840en_US
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorscopusidAtefeh Zarepour / 56700291100
dc.authorwosidAli Zarrabi / U-2602-2019en_US
dc.authorwosidAtefeh Zarepour / AAH-9225-2020en_US
dc.contributor.authorFekrirad, Zahra
dc.contributor.authorBehrooz, Amir Barzegar
dc.contributor.authorGhaem, Shokoofeh
dc.contributor.authorKhosrojerdi, Arezou
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorZarrabi, Ali
dc.contributor.authorArefian, Ehsan
dc.contributor.authorGhavami, Saeid
dc.date.accessioned2022-08-17T06:34:28Z
dc.date.available2022-08-17T06:34:28Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractGlioblastoma (GBM) therapy has seen little change over the past two decades. Surgical excision followed by radiation and chemotherapy is the current gold standard treatment. Immunotherapy techniques have recently transformed many cancer treatments, and GBM is now at the forefront of immunotherapy research. GBM immunotherapy prospects are reviewed here, with an emphasis on immune checkpoint inhibitors and oncolytic viruses. Various forms of nanomaterials to enhance immunotherapy effectiveness are also discussed. For GBM treatment and immunotherapy, we outline the specific properties of nanomaterials. In addition, we provide a short overview of several 3D (bio)printing techniques and their applications in stimulating the GBM microenvironment. Lastly, the susceptibility of GBM cancer cells to the various immunotherapy methods will be addressed.en_US
dc.identifier.citationFekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers (Basel). 2022 Jul 29;14(15):3698. doi: 10.3390/cancers14153698. PMID: 35954362; PMCID: PMC9367505.en_US
dc.identifier.doi10.3390/cancers14153698en_US
dc.identifier.issn2072-6694en_US
dc.identifier.issue15en_US
dc.identifier.pmid9367505en_US
dc.identifier.scopus2-s2.0-85136786278en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.3390/cancers14153698
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3099
dc.identifier.volume14en_US
dc.identifier.wosWOS:000838948900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarepour, Atefeh
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutophagyen_US
dc.subjectGlioblastomaen_US
dc.subjectImmunotherapyen_US
dc.subjectNanomedicineen_US
dc.subjectNanoparticlesen_US
dc.subjectOncolytic Virotherapyen_US
dc.titleImmunology meets bioengineering: Improving the effectiveness of glioblastoma immunotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
cancers-14-03698.pdf
Boyut:
6.18 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu